Proliferative retinopathy is associated with impaired increase in BDNF and RANTES expression levels after preterm birth

Neonatology

Volumn 98, Issue 4, 2010, Pages 409-418

  Hellgren, Gunnel ^a   Willett, Keirnan ^c   Engstrom, Eva ^a   Thorsen, Poul ^d   Hougaard, David M ^e   Jacobsson, Bo ^a,f   Hellstrom, Ann ^b   Lofqvist, Chatarina ^b  

^a QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d KOLDING HOSPITAL   (Denmark)

^e STATENS SERUM INSTITUT   (Denmark)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Brain derived neurotrophic factor; Cytokines; Preterm birth; RANTES; Retinopathy of prematurity

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 5; MESSENGER RNA; RANTES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GESTATIONAL AGE; HUMAN; HYPEROXIA; IMMUNOASSAY; MALE; MOUSE; NEWBORN; NONHUMAN; PERINATAL PERIOD; PREMATURE LABOR; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETINA;

ANIMALS; BIOLOGICAL MARKERS; BIRTH WEIGHT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHEMOKINE CCL5; COMORBIDITY; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, NECROTIZING; FEMALE; FETAL HYPOXIA; GENE EXPRESSION; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MALE; MICE; MICE, INBRED C57BL; RETINA; RETINOPATHY OF PREMATURITY; SWEDEN;

MUS;

EID: 78049474406     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000317779     Document Type: Article

References (51)

1. Fleck BW, McIntosh N: Pathogenesis of retinopathy of prematurity and possible preventive strategies. Early Hum Dev 2008; 84: 83-88.
2. Chen J, Smith LE: Retinopathy of prematurity. Angiogenesis 2007; 10: 133-140.
3. Di Fiore JM, Bloom JN, Orge F, Schutt A, Schluchter M, Cheruvu VK, Walsh M, Finer N, Martin RJ: A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. J Pediatr 2010; 157: 69-73.
4. Gilbert C: Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008; 84:77-82.
5. Seiberth V, Linderkamp O: Risk factors in retinopathy of prematurity. A multivariate statistical analysis. Ophthalmologica 2000; 214:131-135.
6. Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE: Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Nat l Acad Sci USA 2001; 98: 5804-5808.
7. Blodi FC, Silverman WA, Day R, Reese AB: Experiences with corticotrophin (ACTH) in the acute stage of retrolental fibroplasia. AMA Am J Dis Child 1951; 82: 242-245.
8. Brown CA, Corner B: Retrolental fibroplasia; early development and the effect of ACTH in treatment. Br J Ophthalmol 1952; 36: 281-302.
9. Dammann O, Brinkhaus MJ, Bartels DB, Dordelmann M, Dressler F, Kerk J, Dork T, Dammann CE: Immaturity, perinatal inflammation, and retinopathy of prematurity: a multihit hypothesis. Early Hum Dev 2009; 85:325-329.
10. Higuchi A, Ohashi K, Kihara S, Walsh K, Ouchi N: Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factoralpha expression. Circ Res 2009; 104:1058-1065.
11. Sood BG, Madan A, Saha S, Schendel D, Thorsen P, Skogstrand K, Hougaard D, Shankaran S, Carlo W: Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. Pediatr Res 2010; 67: 394-400.
12. BenEzra D, Hemo I, Maftzir G: In vivo angiogenic activity of interleukins. Arch Ophthalmol 1990; 10 8: 573-576.
13. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P: Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA 1987; 84: 5277-5281.
14. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM: Interleukin-8 as a macrophagederived mediator of angiogenesis. Science 1992; 258:1798-1801.
15. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N: Macrophageinduced angiogenesis is mediated by tumour necrosis factoralpha. Nature 1987; 329:630-632.
16. Norrby K: Interleukin-1-alpha and de novo mammalian angiogenesis. Microvasc Res 19 97; 54: 58-64.
17. Gardiner TA, Gibson DS, de Gooyer TE, de la Cruz VF, McDonald DM, Stitt AW: Inhibit ion of t u mor necrosi s f ac tor- a lph a i mproves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol 2005; 166:637-644.
18. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong S, Pravda EA, Majchrzak S, Carper D, Hellstrom A, Kang JX, Chew EY, Salem N Jr, Serhan CN, Smith LE: Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007; 13: 868-873.
19. Adamis AP, Berman AJ: Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008; 30: 65-84.
20. Augustin AJ, Kirchhof J: Inflammation and the pathogenesis of agerelated macular degeneration. Expert Opin Ther Targets 2009; 13: 641-651.
21. Xu H, Chen M, Forrester JV: Parainflammation in the aging retina. Prog Retin Eye Res 2009; 28: 348-368.
22. Lofqvist C, Andersson E, Sigurdsson J, Engstrom E, Hard AL, Niklasson A, Smith LE, Hellstrom A: Longitudinal postnatal weight and insulinlike growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006; 124: 1711-1718.
23. Lofqvist C, Engstrom E, Sigurdsson J, Hard AL, Niklasson A, Ewald U, Holmstrom G, Smith LE, Hellstrom A: Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulinlike growth factor-1 deficit. Pediatrics 2006; 117 : 1930-1938.
24. An international classification of retinopathy of prematurity. The committee for the classification of retinopathy of prematurity. Arch Ophthalmol 1984; 102:1130-1134.
25. Skogstrand K, Thorsen P, Norgaard-Pedersen B, Schendel DE, Sorensen LC, Hougaard DM: Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay w it h x M AP technolog y. C lin Chem 2 005; 51: 1854 -1866.
26. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA: Oxygeninduced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101-111.
27. Wang X, Seed B: A PCR primer bank for quantitative gene expression analysis. Nucl Acids Res 2003; 31:e154.
28. Rao R, Mashburn CB, Mao J, Wadhwa N, Smith GM, Desai NS: Brainderived neurotrophic factor in infants ! 32 weeks gestational age: correlation with antenatal factors and postnatal outcomes. Pediatr Res 2009; 65: 548-552.
29. Sato T, Kusaka S, Shimojo H, Fujikado T: Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology 2009; 116:2165-2169.
30. Shih SC, Ju M, Liu N, Mo JR, Ney JJ, Smith LE: Transforming growth factor beta1 induction of vascular endothelial growth factor receptor 1: mechanism of pericyteinduced vascular survival in vivo. Proc Natl Acad Sci USA 2003; 100:15859-15864.
31. Zhang B, Ohtsuka Y, Fujii T, Baba H, Okada K, Shoji H, Nagata S, Shimizu T, Yamashiro Y: Immunological development of preterm infants in early infancy. Clin Exp Immunol 2005; 14 0: 92-96.
32. Dammann O, Phillips TM, Allred EN, O'Shea TM, Paneth N, Van Marter LJ, Bose C, Ehrenkranz RA, Bednarek FJ, Naples M, Leviton A: Mediators of fetal inflammation in extremely low gestational age newborns. Cy tok ine 2001; 13: 234-239.
33. Pepper MS: Transforming growth factorbeta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997; 8:21-43.
34. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfei ffer A: Def icient activation and different expression of transforming growth factorbeta isoforms in active proliferative diabetic retinopathy and neovascular eye disease. Exp Clin Endocrinol Diabetes 1999; 107:21-28.
35. Zhao S, Overbeek PA: Elevated TGFbeta signaling inhibits ocular vascular development. Dev Biol 2001; 237: 45-53.
36. Perez MT, Caminos E: Expression of brainderived neurotrophic factor and of its functional receptor in neonatal and adult rat retina. Neurosci Lett 1995; 18 3 : 96-99.
37. Ernfors P, Merlio JP, Persson H: Cells expressing mRNA for neurotrophins and their receptors during embryonic rat development. Eur J Neurosci 1992; 4:1140-1158.
38. Ivanova T, Beyer C: Pre- and postnatal expression of brainderived neurotrophic factor mRNA/protein and tyrosine protein kinase receptor B mRNA in the mouse hippocampus. Neurosci Lett 2001; 307: 21-24.
39. Chouthai NS, Sampers J, Desai N, Smith GM: Changes in neurotrophin levels in umbilical cord blood from infants with different gestational ages and clinical conditions. Pediat r Res 2003; 53 : 965-969.
40. Malamitsi-Puchner A, Economou E, Rigopoulou O, Boutsikou T: Perinatal changes of brainderived neurotrophic factor in preand fullterm neonates. Early Hum Dev 2004; 76:17-22.
41. Llamosas MM, Cernuda-Cernuda R, Huerta JJ, Vega JA, Garcia-Fernandez JM: Neurotrophin receptors expression in the developing mouse retina: an immunohistochemical study. Anat Embryol 1997; 195: 337-344.
42. Ghazi-Nouri SM, Ellis JS, Moss S, Limb GA, Charteris DG: Expression and localisation of BDNF, NT4 and TRKB in proliferative vitreoretinopathy. Exp Eye Res 2008; 86: 819-827.
43. Hellstrom A, Engstrom E, Hard AL, Albertsson-Wikland K, Carlsson B, Niklasson A, Lofqvist C, Svensson E, Holm S, Ewald U, Holmstrom G, Smith LE: Postnatal serum insulinlike growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003; 112: 1016-1020.
44. Lofqvist C, Willett KL, Aspegren O, Smith AC, Aderman C, Connor KM, Chen J, Hellstrom A, Smith LE: Quantification and lo calization of the IGF/insulin system expres sion in retinal blood vessels and neurons during oxygeninduced retinopathy in mice. Invest Ophthalmol Vis Sci 2009; 50: 1831-1837.
45. Kazanis I, Bozas E, Philippidis H, Stylianopoulou F: Neuroprotective effects of insulinlike growth factor-I (IGF-I) following a penetrating brain injury in rats. Brain Res 2003; 991: 34-45.
46. Kazanis I, Giannakopoulou M, Philippidis H, Stylianopoulou F: Alterations in IGF-I, BDNF and NT-3 levels following experimental brain trauma and the effect of IGF-I administration. Exp Neurol 2004; 18 6 : 221-234.
47. Matoba N, Yu Y, Mestan K, Pearson C, Ortiz K, Porta N, Thorsen P, Skogstrand K, Hougaard DM, Zuckerman B, Wang X: Differential patterns of 27 cord blood immune biomarkers across gestational age. Pediatrics 2009; 123:1320-1328.
48. Sullivan SE, Staba SL, Gersting JA, Hutson AD, Theriaque D, Christensen RD, Calhoun DA: Circulating concentrations of chemokines in cord blood, neonates, and adults. Pediatr Res 20 02; 51 : 653-657.
49. Sarafidis K, Diamanti E, Taparkou A, Tzimouli V, Drossou-Agakidou V, Kanakoudi-Tsakalidou F: Plasma RANTES increase during the first month of life independently of the feeding mode. Eur J Pediatr 2007; 166: 819-823.
50. Maier R, Weger M, Haller-Schober EM, El-Shabrawi Y, Wedrich A, Theisl A, Aigner R, Barth A, Haas A: Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis 2008; 14: 637-643.
51. Meleth AD, Agron E, Chan CC, Reed GF, Arora K, Byrnes G, Csaky KG, Ferris FL 3rd, Chew EY: Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46:4295-4301.